- Home
- MTVA
MTVA
METAVIA INC
as 06-05-2025 4:00pm EST
Stocks
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 15.1M | IPO Year: | N/A |
| Target Price: | $7.50 | AVG Volume (30 days): | 598.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $5.30 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest METAVIA INC News
MTVA Breaking Stock News: Dive into MTVA Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions
Zacks Small Cap Research
15 days ago
MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…
GlobeNewswire
17 days ago
Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream
PR Newswire
22 days ago
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR Newswire
a month ago
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
PR Newswire
a month ago
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
PR Newswire
a month ago
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
PR Newswire
a month ago
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
Compare MTVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MTVA METAVIA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.